David Tierney has joined Thomas, McNerney & Partners as an entrepreneur-in-residence. He previously was president and CEO of Valera Pharmaceuticals Inc., which was acquired by Indevus Pharmaceuticals.
Thomas, McNerney & Partners, LLC, a health care venture capital firm that invests in life science and medical technology companies, today announced that David S. Tierney, M.D., has joined as an Entrepreneur-in-Residence in the firm's
“David's background is perfect for this role. He has experience as a chief executive with an entrepreneurial company, and also as a drug developer in both specialty and mainstream markets,” said Alex Zisson, partner. “We're looking forward to working with David on ideas for new companies and potential investments.”
Dr. Tierney has more than 18 years of drug development experience, most recently as chief executive officer of Valera Pharmaceuticals, Inc. Prior to joining
“Thomas, McNerney & Partners has a great platform in biopharmaceuticals,” said Dr. Tierney. “The partners have many contacts in industry and academia, and I'm confident that I'll be able to add value to their investment process while we work together to identify my next operating role.”
About Thomas, McNerney & Partners
Thomas, McNerney & Partners is a health care venture capital firm with approximately $600 million under management focused on investing in life science and medical technology companies at all stages of development. In addition to helping entrepreneurs launch companies with seed and early stage funding, the firm provides growth capital to emerging companies to advance clinical development or for product commercialization. Thomas, McNerney & Partners also is involved in spinning out products and divisions from major medical device and pharmaceutical companies, consolidating companies through roll-up strategies and participating in structured financings for public companies as well as recapitalizations. The firm is targeting investments in the pharmaceutical, medical device, biotechnology and diagnostic sectors and in other areas utilizing medical technology innovation. The firm has offices in Stamford, Minneapolis and San Francisco. For further information, please visit http://www.tm-partners.com.